Valuation: GlaxoSmithKline Pharmaceuticals Limited

Market Cap 415B 4.36B 3.9B 3.61B 3.27B 6.11B 6.21B 43.4B 17.17B 217B 16.36B 16.01B 687B P/E 2027 *
35.6x
P/E 2028 * 30.9x
Enterprise Value 415B 4.36B 3.9B 3.61B 3.27B 6.11B 6.21B 43.4B 17.17B 217B 16.36B 16.01B 687B EV / Sales 2027 *
9.74x
EV / Sales 2028 * 8.78x
Free-Float
24.37%
Yield 2027 *
1.2%
Yield 2028 * 1.2%

Last Transcript: GlaxoSmithKline Pharmaceuticals Limited

1 day+1.80%
1 week-4.56%
Current month-11.54%
1 month-13.09%
3 months-2.59%
6 months-1.01%
Current year-0.92%
1 week 2,342.7
Extreme 2342.7
2,509
1 month 2,342.7
Extreme 2342.7
2,986.65
Current year 2,088
Extreme 2088
3,121.1
1 year 2,088
Extreme 2088
3,121.1
3 years 1,387.9
Extreme 1387.9
3,515.95
5 years 1,228
Extreme 1228
3,515.95
10 years 1,020
Extreme 1020
3,515.95
Manager TitleAgeSince
Chief Executive Officer 56 01/12/2022
Director of Finance/CFO - 01/04/2026
Chief Tech/Sci/R&D Officer - 08/07/2024
Director TitleAgeSince
Chairman 73 01/04/2019
Director/Board Member 59 18/05/2020
Director/Board Member 67 16/05/2022
Change 5-day change 1-year change 3-year change Capi.($)
+1.80%-4.56%-10.98%+67.56% 4.29B
+0.45%+3.13%+54.78%+125.16% 1,135B
+0.94%+4.93%+39.94%+78.72% 635B
+0.39%+1.44%+25.75%+97.48% 505B
+1.43%+4.56%+46.20%+66.91% 378B
-3.21%-2.10%+59.78%+33.22% 358B
-0.41%+2.23%+22.48%+48.54% 295B
+0.23%+3.66%+2.45%+23.69% 266B
+1.22%+4.63%+52.71%+64.85% 237B
+1.70%+3.67%+31.73%+102.15% 193B
Average +0.44%+0.82%+32.48%+70.83% 400.79B
Weighted average by Cap. +0.29%+1.62%+41.25%+83.48%

Financials

2027 *2028 *
Net sales 42.57B 447M 400M 370M 335M 627M 638M 4.45B 1.76B 22.26B 1.68B 1.64B 70.5B 47.24B 497M 444M 411M 372M 696M 708M 4.94B 1.96B 24.71B 1.86B 1.82B 78.23B
Net income 11.65B 122M 110M 101M 91.75M 172M 175M 1.22B 482M 6.1B 460M 450M 19.3B 13.42B 141M 126M 117M 106M 198M 201M 1.4B 555M 7.02B 529M 518M 22.22B
Net Debt - -
Projected Income Statement - Annual - GlaxoSmithKline Pharmaceuticals Limited
Logo GlaxoSmithKline Pharmaceuticals Limited
GlaxoSmithKline Pharmaceuticals Limited is an India-based global healthcare company. The Company is engaged in the business of manufacturing, distributing and trading in pharmaceuticals. The Company has three product areas: vaccines, specialty and general medicine. Its general medicines business has a portfolio of medicines in anti-infectives, pain, vitamins medicine, nutritional, hormones, dermatologicals, respiratory and vaccines for adults and children. The Company's general medicine brands include Augmentin, Calpol, Ceftum, Eltroxin, CCM, Neosporin, Betnovate, Tenovate, T-bact and Physiogel. The Company's vaccine brands include Shingrix Herpes Zoster Vaccine, Infanrix Hexa, Synflorix, Boostrix, Havrix, Menveo, Fluarix Tetra and Varilrix. Its specialty medicine brands include Nucala, Seretide, and Trelegy Ellipta. Trelegy Ellipta, single inhaler triple therapy (SITT) for chronic obstructive pulmonary disease (COPD) patients. The Subsidiary of the Company is Biddle Sawyer Limited.
Employees
3,103
Date Price Change Volume
26/10/26 ₹2,448.15 +1.80% 2,133
23/10/26 ₹2,404.80 -1.23% 3,432
22/10/26 ₹2,434.70 -1.18% 1,430
21/10/26 ₹2,463.75 -1.04% 2,472
19/10/26 ₹2,489.70 -2.94% 1,124
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
MarketScreener Ratings - GlaxoSmithKline Pharmaceuticals Limited
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
4
Last Close Price
2,448.15INR
Average target price
3,097.25INR
Spread / Average Target
+26.51%

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - GlaxoSmithKline Pharmaceuticals Limited
  1. Stock Market
  2. Stocks
  3. GLAXO Stock